<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095858</url>
  </required_header>
  <id_info>
    <org_study_id>CD24Fc-005-CATHY</org_study_id>
    <secondary_id>15-4789</secondary_id>
    <secondary_id>FD-OOPD-006089</secondary_id>
    <nct_id>NCT04095858</nct_id>
  </id_info>
  <brief_title>CD24Fc for the Prevention of Acute GVHD Following Myeloablative HSCT</brief_title>
  <acronym>CATHY</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-versus-host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoImmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoImmune, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a randomized, placebo-controlled, double blind, multicenter, phase
      III trial comparing two acute graft-versus-host disease (aGVHD) prophylaxis regimens: CD24Fc
      vs placebo with the standard GVHD prophylaxis of tacrolimus / methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a randomized, placebo-controlled, double blind, multicenter, phase
      III trial comparing two acute graft-versus-host disease (aGVHD) prophylaxis regimens:
      CD24Fc/tacrolimus / methotrexate (CD24Fc/Tac/MTX) versus placebo/tacrolimus / methotrexate
      (placebo/Tac/MTX) in the setting of myeloablative conditioning (MAC), matched unrelated donor
      (MUD) allogeneic hematopoietic stem cell transplantation in patients with acute leukemia
      (AML/ALL) or myelodysplastic syndrome (MDS). The study agent, CD24Fc, will be administered
      through IV infusion on days -1, 14, and 28 at the dose of 480mg, 240 mg and 240mg,
      respectively. The placebo will be 100 ml normal saline IV solution.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>180 day grade III-IV acute GVHD free survival (AGFS)</measure>
    <time_frame>180 days after HCT.</time_frame>
    <description>This is a composite endpoint to determine the Grade III-IV acute GVHD free survival (AGFS) in 180 days after HCT. The onset day of Grade III-IV aGVHD, or death of any cause, which comes the first, will be counted as the event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>One year overall survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>This is to assess the one year overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year disease free survival (DFS)</measure>
    <time_frame>1 year</time_frame>
    <description>This is to assess the one year disease (relapse) free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180 day grade II-IV acute GVHD free survival (AGFS)</measure>
    <time_frame>180 days</time_frame>
    <description>This is a composite endpoint to determine the Grade II-IV acute GVHD free survival (AGFS) in 180 days after HCT. The onset day of Grade II-IV aGVHD, or death of any cause, which comes the first, will be counted as the event.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <condition>Acute Graft Versus Host Disease</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>CD24Fc Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD24Fc: IV infusion, 480 mg (day -1), 240 mg (day +14) and 240 mg (day +28); Tacrolimus: begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted; Methotrexate: given intravenously at a dose of 15 mg/m2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m2/dose on days 3, 6, and 11 after HCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Saline solution): 100ml IV infusion, Day -1, Day 14, Day 28. Tacrolimus: begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted; Methotrexate: given intravenously at a dose of 15 mg/m2/dose once daily on Day 1 after HCT, and at a dose of 10 mg/m2/dose on days 3, 6, and 11 after HCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD24Fc</intervention_name>
    <description>IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.</description>
    <arm_group_label>CD24Fc Treatment</arm_group_label>
    <other_name>Human CD24 and human IgG Fc Fusion Protein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion, 100 ml at Day -1, Day 14, and Day 28.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>IV, 15 mg/m2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.</description>
    <arm_group_label>CD24Fc Treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Trexall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted</description>
    <arm_group_label>CD24Fc Treatment</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>FK506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A prospective patient for allogeneic HCT for a malignant hematologic disorder (see 3
             for eligible diagnoses).

          2. The donor and recipient must have an HLA-8/8 allelic match at the HLA-A, -B, -C, and -
             DRB1 loci. High-resolution typing is required for all alleles for unmatched donors.
             Only matched unrelated donors are acceptable for this trial.

          3. The following diagnoses are to be included:

               1. Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) in first or
                  second remission. Remission is defined as the absence of blasts in the peripheral
                  circulation at the time of enrollment, &lt; 5% blasts in the bone marrow and absence
                  of extramedullary disease including CNS involvement.

               2. Myelodysplastic syndrome (MDS) with intermediate or high-risk IPSS or equivalent
                  IPSS-R score with &lt; 10% blasts in the bone marrow.

          4. Males or non-pregnant, non-lactating females, ≥ 18 years of age. Note there is no
             defined upper age limited, so long as deemed appropriate candidate for myeloablative
             conditioning.

          5. Karnofsky Performance Status &gt;70%, see Appendix A.

          6. Patients must have normal or near normal organ function as defined by their treating
             institutions BMT program clinical practice guidelines. In addition, for purposes of
             this protocol minimum organ function criteria within 30 days of beginning conditioning
             include:

             Eligibility According to Pre HCT Organ Function:

               1. Total bilirubin ≤2.5 mg% (unless from Gilbert's disease or disease-related);

               2. AST(SGOT)/ALT(SGPT) &lt;5.0 X institutional upper limit of normal;

               3. Estimated or actual GFR &gt;50 mL/min/1.73 m2 for patients with creatinine levels
                  above institutional normal (GFR should be corrected for BSA);

               4. Pulmonary Function Tests* DLCO, FEV1, FVC &gt; 50% DLCO should be corrected for
                  hemoglobin;

               5. Ejection Fraction* &gt;50%;

               6. Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) ≤ 5.

             Item d and e may be assessed up to 10 weeks prior to the start of conditioning
             therapy.

          7. Ability to understand and the willingness to sign a written informed consent document.

          8. Women of child bearing potential and men must agree to use contraception prior to
             study entry and through day 100 post HCT (hormonal or barrier method of birth control;
             abstinence). Should a woman become pregnant or suspect she is pregnant while she or
             her partner is on treatment in this study, she should inform her study physician
             immediately. Men treated or enrolled on this protocol must also agree to use adequate
             contraception prior to the study until day 100 post HCT.

        Exclusion Criteria:

          1. Subjects may not have presence of active CNS disease or extramedullary disease.

          2. Prior cytotoxic chemotherapy within 21 days from the initiation of HCT conditioning
             (i.e. intensive induction / consolidation for AML). Note, certain low intensity
             treatments not intended to induce remission but rather stabilize disease are
             acceptable up to 24 hrs prior to initiation of HCT conditioning (i.e. Tyrosine Kinase
             Inhibitor, sorafenib).

          3. Cord blood and haploidentical donors are not eligible.

          4. HLA-mismatch at the HLA-A, -B, -C, and - DRB1 loci. Note, HLA-DQ mismatches are
             permissible.

          5. Pregnant and nursing mothers are excluded from this study. This is because the risk to
             the fetus is unknown.

          6. Any physical or psychological condition that, in the opinion of the investigator,
             would pose unacceptable risk to the patient or raise concern that the patient would
             not comply with protocol procedures.

          7. Uncontrolled infections. Patients still under therapy for presumed or proven infection
             are eligible provided there is clear evidence (radiologic, clinical and/or culture)
             that the infection is well controlled.

          8. Patients seropositive or PCR positive for the human immunodeficiency virus (HIV).
             Patients with evidence of Hepatitis B or Hepatitis C PCR positivity.

          9. Prior HCT (allograft or prior autograft).

         10. Use of T cell depletion either ex vivo or in vivo (i.e. ATG, alemtuzumab) is
             prohibited.

         11. Current or prior diagnosis of antecedent Myelofibrosis is excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Magenau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pavan Reddy</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pan Zheng, MD, PhD</last_name>
    <phone>2027516823</phone>
    <email>pzheng@oncoimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Hongtao Liu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Sherif S Farag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Sunil Abhyankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Nancy Hardy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>John Magenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Joseph Uberti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Samantha Jaglowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State University Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Hong Zheng, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Perelman Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Alison Loren, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

